808127-81-3

Basic information

• Product Name: 4-BroMo-7-hydroxyisoindolin-1-one
• Synonyms: 4-BroMo-7-hydroxyisoindolin-1-one;4-Bromo-7-hydroxy-2,3-dihydro-isoindol-1-one
• CAS NO: 808127-81-3
• Molecular Formula: C8H6BrNO2
• Molecular Weight: 228.04274
• Mol File: 808127-81-3.mol

Chemical Properties

• Boiling Point: 530.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.814±0.06 g/cm3(Predicted)
• PKA: 7.92±0.20(Predicted)
• CAS DataBase Reference: 4-BroMo-7-hydroxyisoindolin-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-7-hydroxyisoindolin-1-one(808127-81-3)
• EPA Substance Registry System: 4-BroMo-7-hydroxyisoindolin-1-one(808127-81-3)

Safety Data

• Hazardous Substances Data: 808127-81-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Bromo-7-hydroxyisoindolin-1-one is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drug candidates with improved properties. Its bromo and hydroxy groups facilitate the construction of complex organic molecules, enhancing the therapeutic potential of resulting compounds.
Used in Agrochemical Development:
In the agrochemical industry, 4-Bromo-7-hydroxyisoindolin-1-one serves as a precursor for the creation of new agrochemicals, leveraging its unique functional groups to improve the effectiveness and selectivity of these products in agricultural applications.
Used in Dye Production:
4-Bromo-7-hydroxyisoindolin-1-one is utilized in the production of dyes, capitalizing on its chemical structure to create dyes with specific color properties and stability, which are essential for various industrial applications.
Used in Organic Chemistry Research:
As a versatile building block, 4-Bromo-7-hydroxyisoindolin-1-one is employed in organic chemistry research for exploring novel reactions and mechanisms, contributing to the advancement of synthetic methodologies and the discovery of new chemical entities.

Upstream product

• 808127-82-4 4-bromo-7-methoxy-2,3-dihydro-1H-isoindol-1-one 
• 6520-83-8 ethyl 2-methoxy-6-methylbenzoate 
• 133379-05-2 ethyl 3-bromo-2-(bromomethyl)-6-methoxybenzoate 

Downstream Products

• 1033809-85-6 7-hydroxy-2,3-dihydro-1H-isoindol-1-one 

Relevant articles and documents

Design and synthesis of pyrrolo[3,2- d ]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: Exploration of novel back-pocket binders

To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI50, 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4-1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.

FUSED HETEROCYCLIC COMPOUND

The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).

Isoindolinone kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS

Compounds having the formula, (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds and compositions containing the compounds.